Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Common Equity (2020 - 2026)

Immuneering's Common Equity history spans 7 years, with the latest figure at $206.5 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 393.56% to $206.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $206.5 million, a 393.56% increase, with the full-year FY2025 number at $218.5 million, up 427.91% from a year prior.
  • Common Equity came in at $206.5 million for Q1 2026, down from $218.5 million in the prior quarter.
  • The five-year high for Common Equity was $228.0 million in Q3 2025, with the low at $28.9 million in Q2 2025.
  • Historically, Common Equity has averaged $110.9 million across 5 years, with a median of $104.0 million in 2023.
  • Biggest five-year swings in Common Equity: surged 604.95% in 2022 and later crashed 56.36% in 2025.
  • Year by year, Common Equity stood at $109.9 million in 2022, then decreased by 17.55% to $90.6 million in 2023, then crashed by 54.31% to $41.4 million in 2024, then soared by 427.91% to $218.5 million in 2025, then fell by 5.48% to $206.5 million in 2026.
  • Business Quant data shows Common Equity for IMRX at $206.5 million in Q1 2026, $218.5 million in Q4 2025, and $228.0 million in Q3 2025.